ALISO VIEJO, Calif., Dec. 10, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and twelve-months ended September 30, 2013.
Quarterly Financial Highlights
•Total company net revenues of $21.7 million
•Gross and net NUEDEXTA® sales increased to $27.7 million and $20.2 million respectively
Help employers find you! Check out all the jobs and post your resume.
